Common iron supplements linked to increased levels of a cancer biomarker

NewsGuard 100/100 Score

A new study conducted at Chalmers University of Technology, Sweden has shown that two commonly available iron compounds increase the formation of a known biomarker for cancer.

Credit: Fahroni/Shutterstock.com

One of the compounds, ferric citrate, is often found in dietary supplements and the other, ferric EDTA, is a commonly used food additive.  

The compounds have previously been shown to contribute to tumor formation in mice, but this is the first time researchers have looked at the potential effects on human cells.

The study looked at the effect of normal supplemental doses of the compounds on two types of cultured human colon cancer cells. As a comparison, the team also looked at the effects of another commonly available iron compound, ferrous sulphate.

The research, which was carried out in collaboration with the UK Medical Research Council and Cambridge University, was recently published in the journal Oncotarget.

The researchers report that while ferrous sulphate had no effect, ferric citrate and ferric EDTA both caused an increase in the levels of a cancer biomarker called amphiregulin, commonly found in colon cancer. The effect was observed even at low supplemental doses.

We can conclude that ferric citrate and ferric EDTA might be carcinogenic, as they both increase the formation of amphiregulin, a known cancer marker most often associated with long-term cancer with poor prognosis.”

Nathalie Scheers, Lead Author

Scheers also warns that many stores and suppliers, including pharmacies, do not actually state what kind of iron compound is present: “Usually it just says 'iron' or 'iron mineral', which is problematic for consumers.”

Although the study was conducted using cells cultured in a laboratory, Scheers says the potential mechanisms and effects observed still call for caution and further investigation.

"Most importantly, researchers and authorities need to start to distinguish between this form of iron and that form of iron. We need to consider that different forms can have different biological effects," she concludes.

Sally Robertson

Written by

Sally Robertson

Sally first developed an interest in medical communications when she took on the role of Journal Development Editor for BioMed Central (BMC), after having graduated with a degree in biomedical science from Greenwich University.

Citations

Please use one of the following formats to cite this article in your essay, paper or report:

  • APA

    Robertson, Sally. (2019, June 20). Common iron supplements linked to increased levels of a cancer biomarker. News-Medical. Retrieved on April 25, 2024 from https://www.news-medical.net/news/20180412/Common-iron-supplements-linked-to-increased-levels-of-a-cancer-biomarker.aspx.

  • MLA

    Robertson, Sally. "Common iron supplements linked to increased levels of a cancer biomarker". News-Medical. 25 April 2024. <https://www.news-medical.net/news/20180412/Common-iron-supplements-linked-to-increased-levels-of-a-cancer-biomarker.aspx>.

  • Chicago

    Robertson, Sally. "Common iron supplements linked to increased levels of a cancer biomarker". News-Medical. https://www.news-medical.net/news/20180412/Common-iron-supplements-linked-to-increased-levels-of-a-cancer-biomarker.aspx. (accessed April 25, 2024).

  • Harvard

    Robertson, Sally. 2019. Common iron supplements linked to increased levels of a cancer biomarker. News-Medical, viewed 25 April 2024, https://www.news-medical.net/news/20180412/Common-iron-supplements-linked-to-increased-levels-of-a-cancer-biomarker.aspx.

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
Breakthrough imaging method enhances precision in prostate cancer treatment